

## **Eastbourne District General Hospital**

Kings Drive Eastbourne East Sussex BN21 2UD

31st October 2025

FOI REF: 25/744

Tel: 0300 131 4500 Website: www.esht.nhs.uk

## FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

1) How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

| • | Avelumab + Axitinib        | 1  |
|---|----------------------------|----|
| • | Axinitib                   | 3  |
| • | Cabozantinib               | 12 |
| • | Everolimus                 | 0  |
| • | Lenvatinib + Everolimus    | 1  |
| • | Lenvatinib + Pembrolizumab | 2  |
| • | Nivolumab monotherapy      | 1  |
| • | Nivolumab + Cabozantinib   | 8  |
| • | Nivolumab + Ipilimumab     | 2  |
| • | Pazopanib                  | 0  |
| • | Pembrolizumab monotherapy  | 3  |
| • | Pembrolizumab + Axitinib   | 0  |
| • | Radiotherapy only          | 0  |

Radiotherapy service is delivered by University Hospitals Sussex NHS Foundation Trust, and their contact details are as follows: By email: <a href="mailto:UHSussex.foi@nhs.net">UHSussex.foi@nhs.net</a>

| • | Sunitinib                                 | 1 |
|---|---|---|
| • | Temsirolimus                              | 0 |
| • | Tivozanib                                 | 0 |
| • | Other active systemic anti-cancer therapy | 0 |

## Palliative care only

East Sussex Healthcare NHS Trust does not centrally record patients being treated for palliative care only. To enable the Trust to provide this information will require a manual review of patients' notes to establish if we hold this information, and discussing each patient with individual clinicians, which we estimate would take in excess of 18 hours. We are therefore applying Section 12(1) to this part of your request.

Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

2) In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

| • | Avelumab + Axitinib (Bavencio + Inlyta)           | 1 |
|---|---|---|
| • | Cabozantinib (Cometriq)                           | 6 |
| • | Nivolumab (Opdivo)                                | 0 |
| • | Nivolumab + Cabozantinib (Opdivo + Cometriq)      | 8 |
| • | Nivolumab + Ipilimumab (Opdivo + Yervoy)          | 0 |
| • | Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda) | 0 |

3) In the last 3 months, how many patients have been initiated\* on the following agents for treatment for Renal Cell Carcinoma?

| • | Nivolumab (monotherapy)                           | 0 |
|---|---|---|
| • | Nivolumab + Ipilimumab                            | 1 |
| • | Nivolumab + Cabozantinib                          | 1 |
| • | Avelumab + Axitinib                               | 0 |
| • | Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda) | 0 |

<sup>\*</sup>Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

4) In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3,M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

| OPCS4<br>Code      | Procedure Description                                | Jul-25 | Aug-25 | Sep-25 | Grand Total |
|--------------------|--|--------|--------|--------|-------------|
| M021               | NEPHRECTOMY AND<br>EXCISION OF PERIRENAL<br>TISSUE   | 1      | 2      | 1      | 4           |
| M022               | NEPHROURETERECTOMY<br>NEC                            | 2      | 3      | 1      | 6           |
| M025               | NEPHRECTOMY NEC                                      | 2      | 1      | 1      | 4           |
| M039               | UNSPECIFIED PARTIAL EXCISION OF KIDNEY               | 2      | 1      | 1      | 4           |
| M101               | ENDOSCOPIC<br>EXTIRPATION OF LESION<br>OF KIDNEY NEC | 2      | 0      | 0      | 2           |
| <b>Grand Total</b> |  | 9      | 7      | 4      | 20          |

5) Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?

The Trust currently has the following trial open to recruitment:

The PARTIAL study: A randomised trial of the clinical and cost effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma.

2 participants have been recruited.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (eshtr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department <a href="mailto:esh-tr.foi@nhs.net">esh-tr.foi@nhs.net</a>